MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-21-2022
Applied Genetic Technologies Corporation Depreciation & Amortization 2011-2026 | AGTC
Annual Depreciation & Amortization Applied Genetic Technologies Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.51 M | 1.46 M | 1.34 M | 1.27 M | 1.18 M | 912 K | 567 K | 376 K | 334 K | 285 K | 262 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.51 M | 262 K | 863 K |
Quarterly Depreciation & Amortization Applied Genetic Technologies Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 372 K | - | - | - | 364 K | 751 K | - | - | 381 K | 771 K | 381 K | - | 322 K | 649 K | 322 K | - | 321 K | 639 K | 321 K | - | 234 K | 544 K | 234 K | - | 201 K | 434 K | 201 K | - | 97 K | 196 K | 97 K | - | 89 K | 184 K | 89 K | - | 79 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 771 K | 79 K | 331 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Altimmune
ALT
|
112 K | $ 3.5 | 4.64 % | $ 308 M |  USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Heron Therapeutics
HRTX
|
2.31 M | $ 0.8 | 2.5 % | $ 133 M | USA |
 |
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
63 K | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | Canada |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M |  Israel |
 |
Immunovant
IMVT
|
377 K | $ 24.27 | 5.61 % | $ 3.68 B | USA |
 |
Incyte Corporation
INCY
|
93.3 M | $ 90.82 | 0.04 % | $ 17.7 B | USA |
 |
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
InMed Pharmaceuticals
INM
|
202 K | $ 0.79 | -3.52 % | $ 1.93 M | Canada |
 |
Inovio Pharmaceuticals
INO
|
2.62 M | $ 1.57 | -0.95 % | $ 34.8 M | USA |
 |
Calithera Biosciences
CALA
|
300 K | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
259 K | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.14 M | - | - | $ 3.74 B | USA |
 |
Clovis Oncology
CLVS
|
8.5 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Compugen Ltd.
CGEN
|
461 K | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
KalVista Pharmaceuticals
KALV
|
941 K | $ 16.93 | -0.41 % | $ 841 M |  Britain |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
CorMedix
CRMD
|
677 K | $ 6.35 | 1.6 % | $ 457 K | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
1.4 M | $ 4.33 | 2.12 % | $ 719 M | Canada |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |